scholarly journals Diagnostic and prognostic value of 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT in a single-center cohort of neuroendocrine tumors

Author(s):  
Jelena Saponjski ◽  
Djuro Macut ◽  
Nebojša Petrovic ◽  
Sanja Ognjanovic ◽  
Bojana Popovic ◽  
...  

IntroductionThe aim was to assess the diagnostic value of 99mTc-Tektrotyd scintigraphy (TCT) and positron emission tomography/computed tomography using F-18 fluorodeoxyglucose (18F-FDG PET/CT) in the detection and follow-up of neuroendocrine tumors (NETs), and their predictive value for disease progression.Material and methodsIn this retrospective cohort, TCT and 18F-FDG PET/CT were performed in 90 patients (37 men, 53 women, mean age 52.7 ±15.1), with NET. Correlation of Ki67 and tumor grade versus Krenning score and SUVmax was assessed, Kaplan-Meier analysis was used for progression-free survival (PFS), and Cox regression analysis was performed to identify the association between progression-related factors and PFS.ResultsOut of 90, true positive TCT was detected in 56 (62.2%) patients, true negative in 19 (21.1%), false positive in 4 (4.4%), false negative in 11 (12.2%), while 18F-FDG PET/CT was true positive in 69 (76.7%) patients, true negative in 10 (11.1%), false positive in 5 (5.5%), false negative in 6 (6.7%). Mean 18F-FDG PET/CT SUVmax was 6.8 ±6.2. Diagnostic sensitivity of TCT was 83.6%, specificity 82.6%, accuracy 83.3% vs. 18F-FDG PET/CT sensitivity was 92.0%, specificity 66.7%, accuracy 87.8%. A significant correlation between Ki67 and SUVmax was found in positive 18F-FDG PET/CT findings, unlike the correlation between Ki67 and Krenning score. Median PFS was 25 months (95% CI: 18.2–31.8), in 18F-FDG PET/CT positive patients 23 months (95% CI: 16.3–29.7) and 18F-FDG PET/CT negative 26 months (p = 0.279). Progression-free survival predictors were SUVmax and Krenning score.ConclusionsIn our study, TCT and 18F-FDG PET/CT have high diagnostic accuracy in detection of NET. Higher Krenning score on TCT and SUVmax in positive 18F-FDG PET/CT findings are predictors of disease progression. 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT can be useful complementary tools in management of patients with NETs and in predicting patients’ outcome.

2021 ◽  
Vol 20 ◽  
pp. 153303382110564
Author(s):  
Na Dai ◽  
Hang Liu ◽  
Shengming Deng ◽  
Shibiao Sang ◽  
Yiwei Wu

Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after allogeneic stem cell transplantation (allo-SCT) in lymphoblastic lymphoma (LBL) patients using Deauville Scores (DS). Materials and Methods: A total of 63 LBL patients who benefited from 18F-FDG PET-CT after allo-SCT in our institution between April 2010 and August 2020 were enrolled in this retrospective study. These above-mentioned patients were divided into two groups based on the Deauville criteria. Diagnostic efficiency of 18F-FDG PET/CT and integrated CT in detecting lymphoma were calculated. Consistencies were evaluated by comparing 18F-FDG PET/CT and integrated CT results through kappa coefficient. Kaplan-Meier method was used in survival analysis, and the log-rank method was adopted in comparisons. Prognostic factor analysis was performed by the Cox regression model. Results: The sensitivity, specificity, positive predictive value, negative predictive value, accuracy of post-SCT 18F-FDG PET-CT were 100%(12/12), 92.2%(47/51), 75.0%(12/16), 100%(47/47) and 93.7%(59/63). The consistency of 18F-FDG PET-CT and integrated CT was moderate(Kappa = .702,P < .001). Positive post-SCT 18F-FDG PET-CT was associated with lower progression-free survival (PFS) but not overall survival (OS) (p = .000 and p = .056, respectively). The 3-year PFS of the PET-positive group and PET-negative group was 18.8% and 70.2%, respectively. Multivariate analysis showed that post-SCT PET-CT findings was an independent prognostic factor for PFS (p = .000; HR, 3.957; 95%CI, 1.839-8.514). Other factors independently affecting PFS were sex (p = .018; HR, 2.588; 95% CI, 1.181 − 5.670) and lactate dehydrogenase (LDH) (p = .005; HR, 3.246; 95% CI, 1.419 − 7.426). However, none of the above-mentioned factors were associated with OS. Conclusions: Collectively, we found that 18F-FDG PET-CT after allo-SCT was a strong indicator for PFS, but not OS, which might provide important evidence for the selection of subsequent treatment regimen for LBL patients. Trial registration number: ChiCTR2100046709.


2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Aurélien Justet ◽  
Astrid Laurent-Bellue ◽  
Gabriel Thabut ◽  
Arnaud Dieudonné ◽  
Marie-Pierre Debray ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e78552 ◽  
Author(s):  
Shaolei Li ◽  
Qingfeng Zheng ◽  
Yuanyuan Ma ◽  
Yuzhao Wang ◽  
Yuan Feng ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1278-1278
Author(s):  
Annalisa Balbo-Musetto ◽  
Riccardo Bruna ◽  
Angela Gueli ◽  
Chiara Saviolo ◽  
Massimo Petracchini ◽  
...  

Abstract Background. The assessment of nodal and extranodal involvement in Hodgkin’s (HL) and non-Hodgkin’s (NHL) lymphoma is mostly performed by Computed Tomography with i.v. iodinated contrast agent (CE-CT) and 18F-FDG Positron Emission Tomography (PET), along with bone marrow (BM) biopsy. Both CE-CT and 18F-FDG-PET require the delivery of considerable dose of ionizing radiation, that may be of concern given the increased risk of secondary malignancies in long surviving patients. Whole body Magnetic Resonance Imaging (Wb-MRI) is a novel and promising radiation-free technique and the development of Diffusion Weighted Imaging (DWI) has enhanced its diagnostic potential. At our Institution, Wb-MRI-DWI has been used as additional diagnostic tool in a series of lymphoma patients at disease onset. The diagnostic accuracy of the procedure is here reported. Patients and Methods. From February 2010 to October 2013, 41 patients underwent the Wb-MRI-DWI procedure, which was added to the standard procedures in order to further investigate possible bone, liver and kidney involvement. Median age of the patients was 49 yrs. (20-76), histological subtypes included 10 Diffuse Large B-Cell (DLB-CL), 13 Follicular (FL), 3 Mantle-cell (MCL), 1 Burkitt’s (BL) Lymphoma and 14 HL. All patients received the diagnostic procedures required for staging definition, including CE-CT, BM biopsy, and 18F-FDG-PET co-registered with low dose unenhanced CT. Nodal and extra-nodal sites were considered pathologic according to standard parameters employed for imaging technique evaluation. For the present analysis, the Gold Standard (GS) assessment was defined based on: i. the information obtained primarily by 18F-FDG PET-CT and secondary by CE-CT findings; ii. the BM histological examination; iii. the modifications before and after therapy for those lesions with discordant definition at diagnosis; iv. for few lesions, with uncertain definition at diagnosis a biopsy procedure was performed and histological data were considered true positive. Results. According to GS, among 1,025 nodal regions analyzed in 41 patients, 217 were judged positive for involvement by lymphoma. CE-CT had 22 false negative and 10 false positive errors, whereas Wb-MRI-DWI erroneously considered involved 6 nodes and failed in recognizing 17 localizations, mostly for misdiagnosed nodes in the mediastinum. There were no errors in nodal assessment by 18F-FDG PET-CT. A total of 458 extranodal sites were evaluated and 37 were considered positive. Compared to GS, 18F-FDG PET-CT had four false negative errors, i.e. no detection of BM (three cases) and spleen (one case) involvement; in addition, 18FDG PET-CT had two false positive results, due to presumed tonsil and BM involvement that were not confirmed on histological examination. CE-CT had 17 false negative errors mainly due to misdiagnosis of BM involvement in 13 out of 14 BM positive cases. Other false negative errors with CE-CT were lack of disease detection in the spleen (1 case), oropharyx (2 cases) and vulva (1 case). Wb-MRI-DWI was unable to detect the gastric involvement in one patient, while no false positive were recorded. The comparative analysis indicates that: i.18F-FDG PET-CT alone overstaged two patients (4.9%) (wrong involvement in BM and tonsil), two patients were understaged due to the failure in recognizing BM involvement; ii. CE-CT alone understaged 12 patients (29%), mainly due to low sensibility in detecting BM involvement; no patient was overstaged by CE-CT; iii. Wb-MRI-DWI alone, in spite of the 24 errors, mainly in nodal misdiagnosis, did not fail the final per-patient staging assessment. Wb-MRI-DWI proved to be the most reliable imaging technique for BM evaluation, with no misjudgment recorded, while 18F-FDG PET-TC was unable to correctly assess BM involvement in four patients and CE-CT in 13. Conclusion. The data indicate that Wb-MRI-DWI is a sensitive and specific imaging technique for malignant lymphoma evaluation. Compared to CE-CT, it detects additional disease that modify clinical stage in a significant percentage of patients, altering their management and outcome. Wb-MRI-DWI is also extremely effective in detecting BM involvement. Thanks to the lack of any radiation exposure and intravenous contrast agent injection, the results here reported further support the use of Wb-MRI-DWI in place of CE-CT for the staging and possibly the follow up monitoring of malignant lymphoma. Disclosures No relevant conflicts of interest to declare.


2017 ◽  
Vol 05 (09) ◽  
pp. E924-E930 ◽  
Author(s):  
Eugénie Rigault ◽  
Laurence Lenoir ◽  
Guillaume Bouguen ◽  
Mael Pagenault ◽  
Astrid Lièvre ◽  
...  

Abstract Background and study aims The relevance of incidental colorectal focal 18F-FDG PET/CT uptake is debatable. All patients who were referred for colonoscopy because of incidental colonic focal FDG uptake were included in this retrospective study. Patients and methods PET/CT imaging characteristics were reviewed by a nuclear physician who was blinded to endoscopic and histopathological findings to determine the location of FDG uptake sites and to measure the maximum standardized uptake values (SUVmax) and metabolic volume (MV). Endoscopic findings were categorized as malignant lesions (ML), high-risk polyps (HRP), low-risk polyps (LRP) or other non-neoplastic lesions (NNL). Results Seventy patients with 84 foci of FDG uptake were included. The proportions of true-positive (lesions found at colonoscopy at the same location) and false-positive (no lesion at colonoscopy) PET/CT findings were 65.5 % (n = 55) and 34.5 % (n = 29). Median SUVmax values did not differ between true-positive and false-positive findings (P = 0.27). Median MV30 values differed significantly between true-positive (5.5 cm3, [3.3 – 10.9 cm3]) and false-positive (9.7 cm3, [5.2 – 40.8 cm3]) findings (P = 0.015). Among the 55 true-positive FDG uptake sites, there were 14 (25.5 %) malignant lesions, 30 (54.5 %) HRP, 4 (7.3 %) LRP, and 7 (12.7 %) NNL. Median MV30 values differed significantly between advanced neoplasia (5.0 cm3, [2.9 – 9.7 cm3]) and other endoscopic findings (9.4 cm3, [5.2 – 39.8 cm3]) (P = 0.001); the AUROC was 0.71. By per-colonic segment analysis, the distribution of true-positive, false-negative, false-positive, and true-negative FDG PET/CT findings was as follows: 21.5 %, 14.2 %, 11.5 %, and 52.8 %, respectively. Conclusion Our study demonstrates that follow-up complete colonoscopy is mandatory in all patients with incidental colorectal focal 18F-FDG PET/CT uptake.


2012 ◽  
Vol 97 (11) ◽  
pp. 4040-4050 ◽  
Author(s):  
Montserrat Ayala-Ramirez ◽  
Cecile N. Chougnet ◽  
Mouhammed Amir Habra ◽  
J. Lynn Palmer ◽  
Sophie Leboulleux ◽  
...  

Context: Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. Objectives: The primary end point was progression-free survival determined by RECIST 1.1 criteria or positron emission tomography with [18F]fluorodeoxyglucose/computed tomography ([18F]FDG-PET/CT), in the absence of measurable soft tissue targets. Secondary endpoints were tumor response according to RECIST criteria version 1.1 or FDG uptake, blood pressure control, and safety. Design: We conducted a retrospective review of medical records of patients with metastatic PHEO/SPGL treated with sunitinib from December 2007 through December 2011. An intention-to-treat analysis was performed. Patients and Setting: Seventeen patients with progressive metastatic PHEO/SPGLs treated at the Institut Gustave-Roussy and MD Anderson Cancer Center. Interventions: Patients treated with sunitinib. Results: According to RECIST 1.1, eight patients experienced clinical benefit; three experienced partial response, and five had stable disease, including four with predominant skeletal metastases that showed a 30% or greater reduction in glucose uptake on [18F]FDG-PET/CT. Of 14 patients who had hypertension, six became normotensive and two discontinued antihypertensives. One patient treated with sunitinib and rapamycin experienced a durable benefit beyond 36 months. The median overall survival from the time sunitinib was initiated was 26.7 months with a progression-free survival of 4.1 months (95% confidence interval = 1.4–11.0). Most patients who experienced a clinical benefit were carriers of SDHB mutations. Conclusion: Sunitinib is associated with tumor size reduction, decreased [18F]FDG-PET/CT uptake, disease stabilization, and hypertension improvement in some patients with progressive metastatic PHEO/PGL. Prospective multi-institutional clinical trials are needed to determine the true benefits of sunitinib.


2012 ◽  
pp. 249-254
Author(s):  
Maria V. Mattoli ◽  
Giorgio Treglia ◽  
Lucia Leccisotti ◽  
Alessandro Giordano

Introduction: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) plays a key role in oncology, and it is now being used increasingly to diagnose, characterize, and monitor disease activity in inflammatory disorders, including vasculitis. Unfortunately, its role in the management of vasculitis is still not well-defined, and clinicians are often unsure how this metabolic imaging technique should be used in these diseases, although its usefulness in diagnosing large-vessel vasculitis has been clearly demonstrated. Materials and methods: We reviewed the literature about the use of PET/CT in the management of vasculitis in an attempt to identify the applications and the limitations of this technique in clinical practice. Results and discussion: Our literature review revealed that 18F-FDG PET/CT is a useful tool for diagnosing vasculitis (especially when the symptoms of the disease are non-specific); guiding biopsy procedures (areas with high glucose consumption); evaluating disease extension; and monitoring treatment responses. The main limitations of this method are the relatively low spatial resolution of the tomograph, which can lead to false-negative results in the presence of small-vessel vasculitis, and risk of false positive results, especially those related to the presence of atherosclerosis and to post-treatment vascular remodeling.


Sign in / Sign up

Export Citation Format

Share Document